[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350488-105":59,"doc-detail-350488-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-validation-of-a-tumor-derived-cxcl1-qpcr-assay-to-support-patient-selection-for-anti-cxcl1-therapeutics-in-bladder-cancer","Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer","","The CXCR2-CXCL1 axis drives tumorigenesis, and CXCL1 is a secreted chemokine involved in tumor progression, angiogenesis, and immune modulation. Immunohistochemistry assessment of CXCL1 is constrained by diffusion and stromal expression. A qPCR-based assay was developed to quantify CXCL1 mRNA in formalin-fixed, paraffin-embedded bladder tumor specimens, followed by analytical validation using muscle-invasive bladder cancer tissues. Performance was tested across preanalytical, analytical, and reproducibility parameters, then applied to 47 patients and benchmarked against RNA-seq TPM, with strong concordance, stable RNA profiles, and cross-platform validity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-validation-of-a-tumor-derived-cxcl1-qpcr-assay-to-support-patient-selection-for-anti-cxcl1-therapeutics-in-bladder-cancer/350488/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-validation-of-a-tumor-derived-cxcl1-qpcr-assay-to-support-patient-selection-for-anti-cxcl1-therapeutics-in-bladder-cancer/350488.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CXCL1 hard to evaluate using immunohistochemistry (IHC) in tumors?","Question",{"text":112,"@type":113},"CXCL1 IHC assessment is limited by diffusion effects and stromal CXCL1 expression, which can obscure tumor-specific signals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the CXCL1 qPCR assay validated analytically?",{"text":117,"@type":113},"Validation covered preanalytical factors (tissue preparation and storage), analytical variables (RNA input, RNA quality, necrosis), and reproducibility parameters.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports assay reliability across tissue types and platforms?",{"text":121,"@type":113},"The assay showed high concordance between fresh frozen and FFPE tissues, robust performance over a defined RNA input range, reliable quantification under substantial necrosis, and strong agreement with RNA-seq expression in the clinical cohort.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350488,1790211587,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Exp Mol Pathol. Author manuscript; available in PMC 2026 June 29. |\n| --- | --- |\n\nPublished in final edited form as:  \nExp Mol Pathol. 2026 June ; 146: 105039. doi:10.1016/j.yexmp.2026.105039 .  \nDevelopment and validation of a tumor-derived CXCL1 qPCRassay to support patient selection for anti-CXCL1 therapeuticsin bladder cancer  \nToru Sakatania, Sunao Tanakaa, Kaoru Murakamia, Cynthia Jinnoa, Francisco Aguilara, Catherine Breseeb, Owen T. M. Chanc, Daniel J. Luthringerd, Alberto Contreras-Sanze, Peter Blacke, Charles J. Rossera,f,g, Hideki Furuyaa,h,*  \naSamuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA  \nbBiostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA, USAcClinical and Translational Research Program, University of Hawaii Cancer Center, Honolulu, HI, USA  \nd Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA, USA e Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada fDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA g Nonagen Therapeutics Corp, Los Angeles, CA 90010, USA  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Corresponding author at: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 110 N. George Burns Road, Davis 2025, Los Angeles, [CA 90048. hideki.furuya@cshs.org](CA 90048. hideki.furuya@cshs.org) (H. Furuya).  \nFigure preparation  \nFig. 1 was created using Microsoft PowerPoint, with selected illustrative elements generated using ChatGPT. Figs. 2–4 were generated using GraphPad Prism version 10 (GraphPad Software Inc., San Diego, CA, USA) .  \nCRediT authorship contribution statement  \nToru Sakatani: Writing – original draft, Visualization, Resources, Methodology, Formal analysis, Data curation. Sunao Tanaka: Methodology, Data curation. Kaoru Murakami: Resources, Methodology, Data curation. Cynthia Jinno: Data curation. Francisco Aguilar: Data curation. Catherine Bresee: Visualization, Formal analysis. Owen T.M. Chan: Data curation. Daniel J. Luthringer: Data curation. Alberto Contreras-Sanz: Resources, Data curation. Peter Black: Resources, Data curation. Charles J. Rosser: Writing – review & editing, Project administration, Funding acquisition, Conceptualization. Hideki Furuya: Writing – review & editing, Writing – original draft, Visualization, Supervision, Project administration, Methodology, Funding acquisition, Formal analysis, Conceptualization.  \nInformed consent statement  \nFor the cohort of the University of British Columbia, written informed consent for participation and publication of anonymized data was obtained from all participants. For the Cedars-Sinai Medical Center cohort, consent for publication was waived by the Institutional Review Boards, as only de-identified archived samples and clinical data were used in accordance with institutional and national regulations.  \nInstitutional review board statement  \nThe study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of Cedars-Sinai Medical Center (IRB\\# STUDY00000451, approved on 14 February 2020) and University of British Columbia (IRB \\# H09–01628, H16–01490, H20–02726, approved on Jan 2009, Jan 2016 and Jan 2020, respectively) . Written informed consent was obtained for the University of British Columbia, while consent was waived for Cedars-Sinai Medical Center due to the use of archived, de-identified samples and clinical data.  \nDeclaration of competing interest  \nCJR is an officer of Nonagen Therapeutics Corporation. The remaining authors have no potential conflicts of interest to disclose, financial or otherwise.  \nAuthor Manuscript Author Manuscript Author ","cbCaig2JxwWYGEtG","https://ap.wps.com/l/cbCaig2JxwWYGEtG","pdf",1138013,16,"English","# Abstract\n## Analytical validation\n## Reproducibility and cross-platform performance\n## Clinical application in muscle-invasive bladder cancer","[{\"question\":\"Why is CXCL1 hard to evaluate using immunohistochemistry (IHC) in tumors?\",\"answer\":\"CXCL1 IHC assessment is limited by diffusion effects and stromal CXCL1 expression, which can obscure tumor-specific signals.\"},{\"question\":\"How was the CXCL1 qPCR assay validated analytically?\",\"answer\":\"Validation covered preanalytical factors (tissue preparation and storage), analytical variables (RNA input, RNA quality, necrosis), and reproducibility parameters.\"},{\"question\":\"What evidence supports assay reliability across tissue types and platforms?\",\"answer\":\"The assay showed high concordance between fresh frozen and FFPE tissues, robust performance over a defined RNA input range, reliable quantification under substantial necrosis, and strong agreement with RNA-seq expression in the clinical cohort.\"}]","Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer | PDF",1790089280,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22bee3ed2d8602d43af658b44e9ec5a0.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e26fd32ae3b16421b2ec1e4d18e3534.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb675ea0aff539844e7dc67abb332f55.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd3853278150b59ac757ac6d15b08b95.webp",980,1268]